Business of regenerative medicine: comparability and the regulatory revolution

 

In the second part of RegMedNet’s expert panel on the business of regenerative medicine, learn more about how comparability and regulation can affect a regenerative medicine’s path to commercialization. Plus, the panelists share their experiences of regulatory systems around the world.

Chaired by Michael May, CCRM, this panel discussion focuses on the key business challenges within regenerative medicine. Joining Michael were four leading voices in regenerative medicine and cell therapy, from research to manufacture: Robert Preti (Hitachi Chemical Advanced Therapeutics Solutions, LLC), Robert Jones (Fisher Bioservices), Carolyn Yeago (Georgia Institute of Technology) and Qasim Rafiq (UCL).

The panel discussion took place in May 2018.

Learn more on RegMedNet’s website.

All other pages contact

For more information, please contact us.
Font Resize
Enable Contrast